Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DNL310 versus idursulfase in pediatric and young adult MPS II
NL-OMON53946Phase 2Recruiting
- Sponsor
- Denali Therapeutics Inc.
- Start
- Feb 2023
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of tividenofusp alfa and idursulfase in mucopolysaccharidosis type 2, sponsored by Denali Therapeutics Inc. Started Feb 2023; status: recruiting.
02
Drugs
tividenofusp alfaidursulfase
03
Conditions
mucopolysaccharidosis type 2
Beyond the preview
Go deeper on NL-OMON53946.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53946.